Burgess C D, Mellsop G W
Department of Medicine, Wellington School of Medicine, New Zealand.
Fundam Clin Pharmacol. 1989;3(1):47-52. doi: 10.1111/j.1472-8206.1989.tb00029.x.
We investigated the pressor response to oral tyramine before and during treatment with moclobemide, a selective monoamine oxidase-A inhibitor, in 10 depressed patients. Before moclobemide therapy, tyramine was associated with a mean (SD) maximum rise in systolic blood pressure of 4.0 (5.2) mmHg, whereas during moclobemide treatment, tyramine was associated with an increase of 24.9 (14.2) mmHg. Only one subject failed to demonstrate an increased pressor response while taking moclobemide. Moclomebide potentiates the pressor response to oral tyramine, but is safer than older nonselective monoamine oxidase inhibitors.
我们对10名抑郁症患者在使用选择性单胺氧化酶-A抑制剂吗氯贝胺治疗前和治疗期间口服酪胺后的升压反应进行了研究。在使用吗氯贝胺治疗前，酪胺使收缩压平均（标准差）最大升高4.0（5.2）mmHg，而在使用吗氯贝胺治疗期间，酪胺使收缩压升高24.9（14.2）mmHg。只有一名受试者在服用吗氯贝胺时未表现出升压反应增强。吗氯贝胺可增强口服酪胺后的升压反应，但比旧的非选择性单胺氧化酶抑制剂更安全。
